Trial Profile

A double-blind, placebo-controlled, dose escalation study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of KCP506 in healthy subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jul 2021 According to a Kineta media release, the company recently completed the single ascending dose (SAD) part of the study and the first participant has been successfully dosed in the multiple ascending dose (MAD) part of the study which enroll up to 24 participants.
15 Dec 2020 According to a Kineta media release, the first participant has been dosed in the trial. Safety, tolerability and pharmacokinetic data expected to read out in the second half of 2021.
15 Dec 2020 Status changed from planning to recruiting, according to a Kineta media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com